Summary
Other Scenarios:
- GDT - WYE
- GDT - BAY
- WYE - BAX
- BAY - BAX
| Buyer: | Guidant Corporation (GDT) | Last Price: | 80.10 | Market Cap.: | 27.14B |
|---|---|---|---|---|---|
| Target: | Baxter International Inc. (BAX) | Last Price: | 38.56 | Market Cap.: | 25.38B |
Lines of Business Summary:
- Guidant Corporation (GDT) competes in 1 industry and 34 product/service groups
- Baxter International Inc. (BAX) competes in 1 industry and 139 product/service groups
- A combined entity will have 0% Product/Service Group overlap
- Guidant Corporation (GDT) has 2 and Baxter International Inc. (BAX) has 0 suppliers that rely on a material % of their business. They share 0 in common.
- Guidant Corporation (GDT) has 0 and Baxter International Inc. (BAX) has 1 customers that derive significant revenue from each. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
*Healthcare |
|
|
860 |
Biopharmaceuticals |
|
314 | |
Healthcare Services |
|
157 | |
Medical Devices |
|
|
247 |
Nutritional Health |
|
23 | |
Outsourced Services |
|
69 |
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 141)
|
Target (Total: 199)
|
Buyern/a |
Target
|
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 15)
|
Target (Total: 22)
|
Buyer (Total: 3)
|
Target (Total: 18)
|
Key Financial Summary:
| Metric | Buyer | Target |
|---|---|---|
| Number of Employees | 13,000 | 47,000 |
| Revenue Per Employee | 255,530.9 | 205,584.5 |
| Total Revenue | 828.2 | 2,409.0 |
| Total Expenses | 715.8 | 2,021.0 |
Other Revenue
|
0.0 | 0.0 |
Cost of Revenue
|
187.8 | 1,357.0 |
SG&A Expense
|
368.2 | 526.0 |
Research & Development
|
171.8 | 138.0 |
Other Operating Expense
|
4.5 | 0.0 |
Operating Income
|
112.4 | 388.0 |
Unusual Income
|
0.0 | 0.0 |
Gross Margin %
|
77.32 | 43.67 |
| Metric | Buyer | Target |
|---|---|---|
Operating Margin %
|
13.57 | 16.11 |
| Total Assets | 6,279.4 | 12,780.0 |
| Return on Equity % | 7.25 | 20.07 |
Cash+ ST Inv. Per Share
|
8.44 | 1.36 |
| Total Debt | 359.0 | 2,405.0 |
Curr Portion of LTD/Cap Lease
|
0.0 | 0.0 |
| Total Debt to Equity | 7.62 | 41.85 |
LT Debt to Capital
|
0.19 | 28.37 |
Fwd P/E
|
47.62 | 18.88 |
Fwd P/Rev
|
6.98 | 2.45 |
| Book Value | 4,711.0 | 5,747.0 |
Individual Company Summary
Focused
Buyer
Focused (
):
*Healthcare > Medical Devices > Cardiology > Surgical > Procedure/Region Specific
Target
Focused (
):
*Healthcare > Medical Devices
Business Description
Buyer
Guidant Corporation (Guidant) provides therapeutic medical solutions for customers, patients and healthcare systems worldwide. The Company's medical technologies are designed for patients suffering from cardiac and vascular disease. Within cardiovascular disease, it develops, manufactures and markets products that focus on the treatment of cardiac arrhythmias, heart failure and coronary, and peripheral disease, including implantable defibrillator systems used to detect and treat abnormally fast heart rhythms (tachycardia) that result in sudden cardiac death, including implantable cardiac resynchronization therapy defibrillator (CRT-D) systems used to treat heart failure; implantable pacemaker systems used to manage slow or irregular heart rhythms (bradycardia), including implantable cardiac resynchronization therapy pacemaker (CRT-P) systems; coronary stent systems for the treatment of coronary artery disease, and angioplasty systems, including dilatation catheters and guidewires.
Target
Baxter International Inc. (Baxter) assists healthcare professionals and their patients with the treatment of complex medical conditions, including hemophilia, immune disorders, infectious diseases, cancer, kidney disease, trauma and other conditions. Baxter's products are used by hospitals, clinical and medical research laboratories, blood and plasma collection centers, kidney dialysis centers, rehabilitation centers, nursing homes, doctors' offices and by patients at home under physician supervision. The Medication Delivery, BioScience and Renal segments comprise Baxter's operations. The Company manufactures products in 28 countries and sells them in over 100 countries.
Product Summary
| Sector | Buyer | Target |
|---|---|---|
*Healthcare |
|
|
Biopharmaceuticals |
|
|
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
|
|
|
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
|
|
|
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
|
|
|
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
|
|
|
Healthcare Services |
|
|
Patient Care
The Paient Care Subsector comprises of companies that provide services to patients for the diagnosis, treatment, and/or prevention of diseases and injuries.
|
|
|
Medical Devices |
|
|
Anesthesiology
The Anesthesiology Subsector includes medical devices that deliver and monitor anesthetics.
|
|
|
Cardiology
The Cardiology Subsector includes medical devices that diagnose, monitor, and treat diseases affecting the heart and proximal blood vessels. Common devices include vital sign monitors, cardiac defibrillators, pacemakers, and other surgical equipment.
|
|
|
Drug Delivery
The Drug Delivery Subsector includes medical devices that facilitate the delivery of medications through different anatomical entryways, including blood vessels, skin, the mouth, and the lungs. Common devices in this sector include vascular access catheters, needles, implants, and inhalers.
|
|
|
Gastroenterology
The Gastroenterology Subsector includes medical devices that diagnosis and treat conditions affecting the stomach and intestinal tract.
|
|
|
General Surgery
The General Surgery Subsector includes medical devices that perform general, non-specialty surgeries; these devices are often general in scope and are used in procedures involving various parts of the body.
|
|
|
Medical Supplies
The Medical Supplies Subsector includes basic and consumable products that are widely used in healthcare settings.
|
|
|
Neurology
The Neurology Subsector includes medical devices that diagnose, monitor and treat neurological disorders.
|
|
|
Ophthalmology
The Ophthalmology Subsector includes medical devices that diagnose and treat eye disorders.
|
|
|
Orthopedics
The Orthopedics Subsector includes medical devices that diagnose and treat musculoskeletal diseases involving muscles, bones and joints.
|
|
|
Respiratory
The Respiratory Subsector includes medical devices that diagnose and treat respiratory diseases.
|
|
|
Transfusion Medicine
The Transfusion Medicine Subsector includes medical devices and accessories that prepare or implement blood transfusion.
|
|
|
Urology
The Urology Subsector includes medical that diagnose and treat urinary tract and male reproductive disorders.
|
|
|
Vascular
The Vascular Subsector includes medical devices that diagnose and treat of conditions affecting the blood vessels.
|
|
|
Nutritional Health |
|
|
Dietary/Naturopathic Supplements
The Dietary/Naturopathic Subsector includes nutritional biochemicals and nutrients derived from natural sources that are intended to support health.
|
|
|
Outsourced Services |
|
|
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
*Healthcare |
|
|
Biopharmaceuticals |
|
|
Allergies |
|
|
Dermatology |
|
|
Antihistamines
Products that inhibit inflammation by blocking the action of histamines on tissues.
Target Products:
|
|
|
Ophthalmology |
|
|
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.
Target Products:
|
|
|
Upper Respiratory |
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Target Products:
|
|
|
Antihistamines/Antitussives
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Target Products:
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Target Products:
|
|
|
Cardiovascular System |
|
|
Heart Disorders |
|
|
Angina |
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat chest pains by inhibiting stimulation of beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
Arrhythmia |
|
|
Adenosine A1 Receptor Agonists
Therapeutics that treat abnormal rhythm of the heart beat by selectively stimulating the A1 adenosine receptor, slowing the speed of AV nodal conduction
Target Products:
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat abnormal rhythm of the heart beat by inhibiting the stimulation of beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of potassium into heart muscle cells.
Target Products:
|
|
|
Myocardial Infarction (MI) |
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat irreversible damage to the heart muscle by blocking the beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
Vascular Disorders |
|
|
Hypertension |
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat high blood pressure by stimulating the alpha adrenergic receptors of the heart muscle.
Target Products:
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
Hypovolemia |
|
|
Plasma Volumizers |
|
|
Albumin-Based
Therapeutics based on plasma proteins that treat a decrease in circulating fluid (plasma) in the body by increasing plasma volume.
Target Products:
|
|
|
Thromboembolism |
|
|
Anticoagulating Agents (Anticoagulants) |
|
|
Platelet Aggregation Inhibitors |
|
|
Phosphodiesterase Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing platelets from clumping together.
Target Products:
|
|
|
Digestive System |
|
|
Gastrointestinal Tract Disorders |
|
|
Gastroesophageal Disorders |
|
|
Gastroesophageal Reflux Disease (GERD) |
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat Gastroesophageal Reflux Disease (GERD) by blocking dopamine receptor and stimulating gastrointestinal movement without stimulating secretions from the pancreas, stomach or gall bladder.
Target Products:
|
|
|
Nausea/Vomiting |
|
|
Serotonin Receptor Antagonists
Therapeutics that treat nausea and vomiting by blocking the serotonin receptors.
Target Products:
|
|
|
Hematology |
|
|
Hemophilia |
|
|
Hemophilia A |
|
|
Clotting Agents
Therapeutics that aid in blood coagulation.
Target Products:
|
|
|
Hemophilia B |
|
|
Clotting Agents
Therapeutics that assist in blood coagulation.
Target Products:
|
|
|
Red Blood Cell (RBC) Disorders |
|
|
Anemia |
|
|
Recombinant Human Erythropoietins
Therapeutics that treat conditions characterized by reduced delivery of oxygen to body tissues by stimulating red blood cell production.
Target Products:
|
|
|
Serum Factor Disorders |
|
|
Hypoalbuminemia |
|
|
Albumin-Based
Therapeutics based on plasma proteins that treat low levels of serum albumin.
Target Products:
|
|
|
Immunology |
|
|
Autoimmune Disorders |
|
|
Arthritis |
|
|
Rheumatoid Arthritis (RA) |
|
|
Analgesics |
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Target Products:
|
|
|
Idiopathic Thrombocytopenia Purpura (ITP) |
|
|
Immunoglobulins
Therapeutics that treat a decrease in platelets by neutralizing autoantibodies with therapeutic antibodies.
Target Products:
|
|
|
Kawasaki Syndrome |
|
|
Immunoglobulins
Therapeutics that treat Kawasaki Syndrome by neutralizing autoantibodies with therapeutic antibodies.
Target Products:
|
|
|
Immune Deficiency Disorders |
|
|
Primary Immunodeficiency Diseases |
|
|
Immunoglobulins
Therapeutics that treat primary immunodeficiency diseases by providing the body with therapeutic antibodies.
Target Products:
|
|
|
Infectious Diseases |
|
|
Bacterial |
|
|
Antibacterial Agents |
|
|
Broad Spectrum |
|
|
Antibiotics |
|
|
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.
Target Products:
|
|
|
Penicillin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis during active multiplication.
Target Products:
|
|
|
Tetracyclines
Therapeutics that treat a wide variety of infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Target Products:
|
|
|
Narrow Spectrum |
|
|
Respiratory System |
|
|
Bronchitis |
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections leading to inflammation of the bronchi in the lungs by inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.
Target Products:
|
|
|
Pneumonia |
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat inflammation of the lungs caused by bacterial infection by inhibiting folic acid synthesis and bacterial growth.
Target Products:
|
|
|
Tuberculosis |
|
|
Antitubercular Agents
Therapeutics that treat a bacterial infection of the lung by inhibiting bacterial and mycobacterial RNA synthesis.
Target Products:
|
|
|
Urology |
|
|
Urinary Tract Infections (UTI) |
|
|
Antibacterial Agents (Antibiotics) |
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections of the urinary tract by inhibiting dihydrofolate reductase resulting in decreased bacterial nucleic acid/protein production.
Target Products:
|
|
|
Vaccines |
|
|
Bacterial |
|
|
Combination |
|
|
Diphtheria/Tetanus/Acellular Pertussis (DTaP)
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause diphtheria, tetanus, and acellular pertussis.
Target Products:
|
|
|
Mycological (Fungal) |
|
|
Antifungal Agents |
|
|
Narrow Spectrum |
|
|
Dermatology |
|
|
Tinea Barbae |
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the bearded area by inhibiting the biosynthesis of cell walls.
Target Products:
|
|
|
Tinea Capitis |
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the scalp by inhibiting biosynthesis of cell walls.
Target Products:
|
|
|
Tinea Corporis (Ringworm) |
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by inhibiting the biosynthesis of cell walls.
Target Products:
|
|
|
Tinea Cruris (Jock Itch) |
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the groin and perineum by inhibiting the biosynthesis of cell walls.
Target Products:
|
|
|
Tinea Pedis |
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the feet by inhibiting the biosynthesis of cell walls.
Target Products:
|
|
|
Tinea Unquium |
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of the nails by inhibiting the biosynthesis of cell walls.
Target Products:
|
|
|
Tinea Versicolor |
|
|
Penicillin Derivatives
Therapeutics that treat fungal infections of skin exposed to the sun characterized by patches of depigmentation by inhibiting the biosynthesis of cell walls.
Target Products:
|
|
|
Nervous System |
|
|
Cryptococcal Meningitis |
|
|
Triazoles
Therapeutics that treat fungal infections of lining of the brain and the spinal cord by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
Otolaryngology (Ear/Nose/Throat) |
|
|
Esophageal Candidiasis |
|
|
Triazoles
Therapeutics that treat fungal infections of the esophagus caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
Oropharyngeal Candidiasis |
|
|
Azoles |
|
|
Triazoles
Therapeutics that treat fungal infections of the mouth and pahrynx caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
Urology |
|
|
Vaginal Candidiasis |
|
|
Azoles |
|
|
Triazoles
Therapeutics that treat fungal infections of the female reproductive organ caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.
Target Products:
|
|
|
Viral |
|
|
DNA Viruses |
|
|
Herpesvirus |
|
|
Herpes Simplex Type 1 |
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections characterized by recurrent cold sores and fever blisters by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Target Products:
|
|
|
Herpes Simplex Type 2 |
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections characterized by recurring outbreaks of painful genital lesions by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Target Products:
|
|
|
Varicella Zoster |
|
|
Herpes Zoster (Shingles) |
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections that cause shingles in adults by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Target Products:
|
|
|
Varicella (Chickenpox) |
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections that cause chicken pox in children by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Target Products:
|
|
|
Musculoskeletal System |
|
|
Skeletal Disorders |
|
|
Joint Disorders |
|
|
Osteoarthritis (OA) |
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Target Products:
|
|
|
Rheumatoid Arthritis (RA) |
|
|
Analgesics |
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Target Products:
|
|
|
Neurology |
|
|
Neurological Disorders |
|
|
Headaches |
|
|
Vascular (Migraine) |
|
|
Prophylactic Treatments |
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat Migraine by inhibiting stimulation of beta adrenergic receptors.
Target Products:
|
|
|
Neuromuscular Disorders |
|
|
Myasthenia Gravis (MG) |
|
|
Cholinesterase Inhibitors
Therapeutics that treat Myasthenia Gravis by maintaining the transmission of nerve impulses by inhibiting the enzyme that breaks down acetylcholine.
Target Products:
|
|
|
Parkinson`s Disease (PD) |
|
|
Adjunctive Treatments |
|
|
Skeletal Muscle Relaxing Agents/Analgesics
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by relaxing motor muscles and relieving pain.
Target Products:
|
|
|
Psychiatric Disorders |
|
|
Anxiety |
|
|
Generalized Anxiety Disorder (GAD) |
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat anxiety by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Target Products:
|
|
|
Sleep Disorders |
|
|
Insomnia |
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.
Target Products:
|
|
|
Oncology |
|
|
Hematology |
|
|
Leukemia |
|
|
Lymphoid |
|
|
Chronic |
|
|
Lymphocytic (CLL) |
|
|
Immunoglobulins
Therapeutics that treat and manage slowly progressing cancers of lymphocytic cells by providing a therapeutic protein.
Target Products:
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.
Target Products:
|
|
|
Pain Management |
|
|
Anesthesia |
|
|
General (Systemic) |
|
|
Adjunctive |
|
|
Acetylcholine Blocking Agents
Therapeutics that inhibit neuromuscular activity by competing with acetylcholine at the cholinergic receptors resulting in neuromuscular blockage.
Target Products:
|
|
|
Ether-Based Agents
Therapeutics that result in anesthesia due to interfering with the physiological functioning of nerve cell membranes in the brain.
Target Products:
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that result in anesthesia by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Target Products:
|
|
|
Hypnotic Agents (Sedatives)
Therapeutics that result in anesthesia by inducing sleep. These therapeutics have no analgesic action.
Target Products:
|
|
|
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters both the perception of pain as well as the emotional response to pain.
Target Products:
|
|
|
Reversal |
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Antagonists
Therapeutics that reverse general anesthesia by competitively inhibiting benzodiapizines at the GABA receptors, thus reducing their effect and reversing the anesthesia.
Target Products:
|
|
|
Narcotics |
|
|
Analgesics/Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters the both the perception of pain as well as the emotional response to pain.
Target Products:
|
|
|
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain.
Target Products:
|
|
|
Non-Narcotics |
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain by non-specifically inhibiting the action of cyclooxygenase.
Target Products:
|
|
|
Respiratory System |
|
|
Lower Respiratory Tract Disorders (Lung Disorders) |
|
|
Bronchitis |
|
|
Complications |
|
|
Bacterial Infections |
|
|
Antibacterial Agents (Antibiotics) |
|
|
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections by inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.
Target Products:
|
|
|
Emphysema |
|
|
Congenital |
|
|
Proteinase Inhibitors
Therapeutics that treat emphysema by providing certain proteins. The body's lack of ability to manufacture these proteins results in the disease state.
Target Products:
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
Upper Respiratory Tract Disorders |
|
|
Coughs/Colds |
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Target Products:
|
|
|
Antihistamines/Antitussives
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Target Products:
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and reduces the amount of mucous build up.
Target Products:
|
|
|
Antihistamines/Decongestants/Opioids
Therapeutics that treat coughs and colds by suppressing histamine-related inflammation, preventing congestion and altering both the perception and emotional response to pain.
Target Products:
|
|
|
Antihistamines/Opioids
Therapeutics that treat coughs and colds by suppressing histamine-related inflammation and altering both the perception and emotional response to pain.
Target Products:
|
|
|
Surgery |
|
|
General |
|
|
Acute Tissue Oxygen Deficiency |
|
|
Perfluorochemicals
Therapeutics that are made up mainly of carbon and fluorine that has oxygen carrying properties.
Target Products:
|
|
|
Complications |
|
|
Hemorrhage |
|
|
Fibrinolysis Inhibitors
Therapeutics that treat complications involving bleeding after surgical procedures by inhibiting the breakdown of fibrin in blood clots.
Target Products:
|
|
|
Toxicology |
|
|
Substance Abuse |
|
|
Withdrawal |
|
|
Alcohol |
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat alcohol withdrawal by increasing the effect of GABA at the relevant neuroreceptors.
Target Products:
|
|
|
Narcotics |
|
|
Opioid Antagonists
Therapeutics that treat narcotic addiction by blocking the effect of opioids.
Target Products:
|
|
|
Urology |
|
|
Urological Disorders |
|
|
Bladder |
|
|
Cystitis |
|
|
Urotoxin Neutralizing Agents
Therapeutics that inhibit cystis induced by toxic therapeutics by neutralizing these therapeutics.
Target Products:
|
|
|
Healthcare Services |
|
|
Patient Care |
|
|
Ambulatory/Outpatient |
|
|
Specialized |
|
|
Dialysis
The process of cleansing the blood of end stage renal disease patients (ESRD) through the use of a semipermeable membrane, which allows waste products to pass but retains most of the blood's normal constituents. Dialysis services can be provided in outpatient settings, in patients' home, or in hospitals as a contractor.
Target Products:
|
|
|
Medical Devices |
|
|
Anesthesiology |
|
|
Diagnostic |
|
|
Monitoring |
|
|
Systems |
|
|
Consciousness Monitoring
Systems designed to monitor the effect of anesthesia on patients during surgery.
Target Products:
|
|
|
Surgical |
|
|
General Procedure |
|
|
Delivery Systems |
|
|
Gas |
|
|
Breathing Accessories
Ancillary devices used to aid the administering of inhaled anesthetics, such as breathing bags and breathing masks.
Target Products:
|
|
|
Breathing Circuits
Devices which assist in physical mechanism of breathing.
Target Products:
|
|
|
Percutaneous (Subcutaneous/Intramuscular/Intravenous) |
|
|
Fluid Administration Sets
Intravenous fluid administration sets used to deliver anesthesia.
Target Products:
|
|
|
Pumps/Systems
Devices used to pump intravenous fluids at a consistent programmed rate.
Target Products:
|
|
|
Viscoelastics
Materials that can be applied to the skin and decrease resistance of to injected drugs.
Target Products:
|
|
|
Procedure/Region Specific |
|
|
Delivery Systems |
|
|
Epidural
Devices used to inject anesthetic into the epidural space to numb the legs and abdomen, which include catheters, needles, syrninges and other prepackaged kits.
Target Products:
|
|
|
Nerve Block
Devices used to assist in the delivery of nerve block anesthetic, which include catheters, needles and other prepackaged kits.
Target Products:
|
|
|
Spinal
Devices used to inject anesthetic into the spine, which include catheters, needles and other prepackaged kits.
Target Products:
|
|
|
Cardiology |
|
|
Diagnostic |
|
|
Monitoring |
|
|
Monitors |
|
|
Telemetry |
|
|
Telemetry Systems
Complete systems or devices used to facilitate transfer of vitals monitoring data from the patient's site to a central monitor.
Buyer Products:
|
|
|
Surgical |
|
|
General Procedure |
|
|
Accessories |
|
|
Guidewires
A small wire-like device that is threaded through a catheter to the site of interest for delivery of another apparatus like a stent.
Buyer Products:
|
|
|
Vessel Closure
Devices used to close heart blood vessels.
Target Products:
|
|
|
Instruments |
|
|
Electrical |
|
|
Irrigation Blowers/Misters
Instruments used to add moisture or aid onto cardiac tissue during surgery.
Buyer Products:
|
|
|
Procedure/Region Specific |
|
|
Arrhythmia |
|
|
External Pacing |
|
|
Dual Chamber
Device that is capable of regulating the electrical stimulation rhythm of two heart chambers.
Buyer Products:
|
|
|
Implants |
|
|
Implantable Cardioverter Defibrillators (ICD) |
|
|
Accessories
Components used in conjunction with ICD implants, such as programmers and lead wires.
Buyer Products:
|
|
|
Non-Rate Adaptive
An implantable device that detects ventricular tachycardia and fibrillation and automatically delivers an electrical shock to restore normal heartbeat, but does not change its function due to physical activity the heart is enduring.
Buyer Products:
|
|
|
Rate Adaptive
An implantable device that detects ventricular tachycardia/fibrillation and automatically delivers an electrical shock to restore normal heartbeat, and adapts to the present rate of the physical activity the heart is under.
Buyer Products:
|
|
|
Pacemakers |
|
|
Accessories
Components used in conjunction with pacemakers, such as programmers and lead wires.
Buyer Products:
|
|
|
Non-Rate Adaptive
Pacemakers (including single chamber and dual chamber) which do not automatically adapt to the changing heart rate of the patient.
Buyer Products:
|
|
|
Rate Adaptive
Pacemakers (including single chamber and dual chamber) which automatically adapt to the changing heart rate of the patient.
Buyer Products:
|
|
|
Microwave Surgical Ablation Systems
Systems used to restore normal heart rhythm by using microwave energy to destroy cells that cause abnormal electrical impulses.
Buyer Products:
|
|
|
Cardiopulmonary Support |
|
|
Minimally Invasive |
|
|
Endovascular Bypass Systems
Minimally invasive device that provides cardiopulmonary support by bypassing the heart.
Buyer Products:
|
|
|
Coronary Artery Bypass Graft (CABG) |
|
|
Invasive (Open Heart) |
|
|
Accessories
Various instruments used to assist in open heart bypass surgery, such as sutures, needles and vessel occluders.
Buyer Products:
|
|
|
Manual Instruments
Various devices used to perform open heart bypass surgery that do not require electrical power, such as heart positioners, stablizers and retractors.
Buyer Products:
|
|
|
Shunts
Devices used to divert blood flow in order to perform surgical procedure.
Buyer Products:
|
|
|
Minimally Invasive |
|
|
Manual Instruments
Manual surgical instruments used to perform minimally invasive coronary bypass surgery, such as retractors, forceps, clamps, clip applicators, stablilizers, bisectors and other similar items.
Buyer Products:
|
|
|
Revascularization |
|
|
Atherectomy |
|
|
Directional Catheters
Catheter that is able to be manually directed one way or the other.
Buyer Products:
|
|
|
Percutaneous Transluminal Coronary Angioplasty (PTCA) |
|
|
Catheters |
|
|
Balloon |
|
|
Over-The-Wire
A balloon catheter that is put into position by passing it over the guidewire all the way to the coronary blockage site of interest.
Buyer Products:
|
|
|
Rapid Exchange
An angioplasty balloon catheter that provides flexibility, trackability, tactile feedback, and ease of use.
Buyer Products:
|
|
|
Guiding
Catheter used to guide the balloon into place in the coronary artery.
Buyer Products:
|
|
|
Restenosis Prevention |
|
|
Stents Systems |
|
|
Coated
Stent systems that are coated with pharmaceuticals that aid the stent in preventing restenosis.
Buyer Products:
|
|
|
General
Stent systems that are not coated with additional pharmaceuticals indicated to prevent restenosis.
Buyer Products:
|
|
|
Valvoplasty |
|
|
Valves |
|
|
Aortic Valved Conduits |
|
|
Mechanical
A channel through the aorta the blood can flow through that has a valve to stop or control the flow.
Buyer Products:
|
|
|
Drug Delivery |
|
|
Infusion Therapy |
|
|
Accessories |
|
|
Admixture Systems
Medical systems designed to combine multiple medications for delivery to the patients
Target Products:
|
|
|
Closed Blood Sampling Systems
Sampling systems which do not use needles to access infusion systems to obtain a blood sample.
Target Products:
|
|
|
Filtration Products
Device used to filter fluids for infusion.
Target Products:
|
|
|
Fluid Administration/Extension Sets
Filtered IV sets designed for infusion therapy.
Target Products:
|
|
|
Fluid Warmers
Medical devices used to maintain the warmth of the medical products prior to and during the infusion process.
Target Products:
|
|
|
Needleless Fluid Administration/Extension Sets
Valve systems designed to work without needles to prevent patient injuries.
Target Products:
|
|
|
Pump Sets
Pump sets designed specifically for infusion therapy.
Target Products:
|
|
|
Delivery Systems |
|
|
Elastomeric Infusors
Infusion delivery system designed for small-volume fluid transmission (home use).
Target Products:
|
|
|
Pumps |
|
|
Multiple Channel
Multiple channel pump designed to deliver more than one infusion therapy to patients.
Target Products:
|
|
|
Single Channel
Single channel pump designed to deliver only one infusion therapy to patients.
Target Products:
|
|
|
Syringe
Syringe used in place of a pump to deliver infusion therapy.
Target Products:
|
|
|
Integrated/Comprehensive Systems
Complete infusion systems that include pumps, monitoring devices and other accessories.
Target Products:
|
|
|
Vascular Access |
|
|
Peripheral Intravenous Catheters |
|
|
Infusion Sets
Complete infusion sets containing peripheral intravenous catheters.
Target Products:
|
|
|
Standard
Non-ported peripheral intravenous catheters.
Target Products:
|
|
|
Gastroenterology |
|
|
Surgical |
|
|
General Procedure |
|
|
Minimally Invasive/Oral Percutaneous Rectal |
|
|
Region Specific |
|
|
Biliary |
|
|
Stents Systems
A device used to keep open the bile duct.
Buyer Products:
|
|
|
Treatment |
|
|
Stomach |
|
|
Tubes |
|
|
Feeding
A tube that carries food to the stomach.
Target Products:
|
|
|
General Surgery |
|
|
Invasive |
|
|
Surgical-Site Treatments |
|
|
Sealants |
|
|
Hemostatic |
|
|
Delivery Systems
Medical devices designed to deliver hemostatic sealants to the surgical site
Target Products:
|
|
|
Sponges
Microfibrillar sponge used when conventional hemostasis procedures are not effective.
Target Products:
|
|
|
Topical
Topical mixture used when conventional hemostasis procedures are not effective.
Target Products:
|
|
|
Medical Supplies |
|
|
Diagnostic |
|
|
Clinical Examination |
|
|
Basic Examining Tools
Medical instruments used to examine and monitor basic physiological functions, such as reflex, blood pressure, heart rate, and pulmonary capacity. These instruments include stethoscopes, sphygmomanometers, percussion hammers and other similar items.
Target Products:
|
|
|
Safety and Sterilization |
|
|
Safety |
|
|
Waste Management
Products used to control and contain biohazardous materials, such as chemical waste, fluid waste, and solid waste. These products may include bags, containers, and other more advanced waste treatment systems.
Target Products:
|
|
|
Neurology |
|
|
Diagnostic |
|
|
Monitoring |
|
|
Monitors |
|
|
Electroencephalograph (EEG) |
|
|
Intraoperative
An electroencephalograph that is used during surgery.
Target Products:
|
|
|
Surgical |
|
|
General Procedure |
|
|
Surgical Sealants
A glue like material, made up of biomaterials, that is used to close up surgical incisions.
Target Products:
|
|
|
Ophthalmology |
|
|
Surgical |
|
|
Procedure/Region Specific |
|
|
Cataract |
|
|
Viscoelastics
Material that can be applied to decrease resistance between two parts of the eye and promote healing and repair of damaged eye tissue.
Target Products:
|
|
|
Orthopedics |
|
|
Surgical |
|
|
Procedure Specific |
|
|
Bone Loss Reconstruction |
|
|
General |
|
|
Bone Fillers
Devices used to fill the formed bone cavity with hardening material.
Target Products:
|
|
|
Respiratory |
|
|
Treatment |
|
|
Assisted Breathing |
|
|
Intubation |
|
|
Breathing Circuits
Instrument used to measure respiratory parameters such as pressure.
Target Products:
|
|
|
Transfusion Medicine |
|
|
Blood Collection |
|
|
Accessories |
|
|
Collection/Storage
Devices, usually polymer plastic bags used for collection and subsequent storage of blood and blood components. Specific additives may or may not be incorporated to prevent the collected blood from clotting.
Target Products:
|
|
|
Apheresis Systems |
|
|
Plasma
Systems which separate and collect the plasma component of human blood while returning other blood components to the donor.
Target Products:
|
|
|
Platelets
Systems which separate and collect the platelet cell component of human blood while returning other blood components to the donor.
Target Products:
|
|
|
Red Blood Cells
Systems which separate and collect the red cell component of human blood while returning other blood components to the donor.
Target Products:
|
|
|
Blood Washers
Instruments used to wash blood cells in preparation for usage; they are often used to prepare frozen red blood cells for transfusion.
Target Products:
|
|
|
Filtration Systems
Medical devices used to filter leukocytes from blood during the transfusion process.
Target Products:
|
|
|
Viral Inactivation |
|
|
Plasma
Medical devices and technology which destroy infectious agents such as viruses in donor plasma without damaging the integrity of the plasma proteins.
Target Products:
|
|
|
Platelets
Medical devices and technology which destroy infectious agents such as viruses in blood products (platelets) without damaging the integrity of the donor platelet cells.
Target Products:
|
|
|
Red Blood Cells
Medical devices and technology which destroy infectious agents such as viruses in donor blood without damaging the integrity of the donor red blood cells.
Target Products:
|
|
|
Urology |
|
|
Surgical |
|
|
General Procedure |
|
|
Minimally Invasive/Cystoscopy |
|
|
Irrigation Pumps/Systems
Surgical instruments that pump fluids to irrigate/moisten the surface of the urinary organs
Target Products:
|
|
|
Procedure/Region Specific |
|
|
Incontinence |
|
|
Female |
|
|
Bladder Neck Suspension |
|
|
Distention Systems
Surgical instruments used to expand the bladder with fluids, including water, to improve urinary bladder control in female incontinence patients
.
Buyer Products:
|
|
|
Tacking Systems
Complete set of instruments used to anchor something in place.
Buyer Products:
|
|
|
Treatment |
|
|
Renal |
|
|
Hemodialysis |
|
|
Components |
|
|
Access Grafts
Pieces of material or tissue used to cover up holes made in the body for hemodialysis access.
Buyer Products:
|
|
|
Concentrates
Chemicals used in hemodialysis.
Target Products:
|
|
|
Dialysate Parameter Monitors
Medical products used to monitor parameters such as fluid pressure, concentration, pH etc. during dialysis procedures.
Target Products:
|
|
|
Filtration |
|
|
Dialyzers
The instrument or medium used to effect chemical dialysis which allows for the diffusion of waste products and excess water into a dialysate solution.
Target Products:
|
|
|
Hemofilters
Filters used to separate the blood from the waste components during dialysis
through a convection process by creating negative pressure to draw out solute particles without using a dialysate solution.
Target Products:
|
|
|
Systems
A complete set of devices that act as a kidney to remove waste from the circulatory system.
Target Products:
|
|
|
Peritoneal Dialysis |
|
|
Components |
|
|
Solutions
Chemical agents used in peritoneal dialysis.
Target Products:
|
|
|
Systems |
|
|
Automated Peritoneal Dialysis (APD)
Complete set of instruments and devices that cycle solution to and from the patient's peritoneum during sleep.
Target Products:
|
|
|
Continuous Ambulatory (CAPD)
Complete set of instruments and devices that perform peritoneal dialysis that can be moved around with the patient.
Target Products:
|
|
|
Vascular |
|
|
Surgical |
|
|
General Procedure |
|
|
Accessories |
|
|
Guidewires
Surgical instruments used to lead other medical devices such as catheters into specific areas of the blood vessels
Buyer Products:
|
|
|
Vessel Closure
Devices used to close and repair vascular structures, including both complete systems and associated clamps, felts and pledgets.
Target Products:
|
|
|
Vessel Harvesting |
|
|
Systems
Medical instruments necessary for vessel harvesting procedures sold as a complete system.
Buyer Products:
|
|
|
Procedure/Region Specific |
|
|
Patency |
|
|
Thrombolytic/Embolytic Catheters
Intravascular catheters used to break up plaque build-up and obstructions in blood vessels; thrombus and embolus are composed primarily of platelets/fibrin and platelets/leukocytes combinations respectively.
Buyer Products:
|
|
|
Percutaneous Transluminal Coronary Angioplasty (PTCA) |
|
|
Catheters |
|
|
Balloon
Catheters equipped with an expanding balloon at the tip
Buyer Products:
|
|
|
Guiding
Catheters used to guide the balloon catheter in place.
Buyer Products:
|
|
|
Restenosis Prevention |
|
|
Stents Systems |
|
|
Biliary Tract
Stent inserted into the biliary tract in the liver to prevent future obstruction.
Buyer Products:
|
|
|
Peripheral
Stents designed to be placed in peripheral blood vessels.
Buyer Products:
|
|
|
Nutritional Health |
|
|
Dietary/Naturopathic Supplements |
|
|
General Health
Products consisting of dietary/naturopathic supplements that are intended to support general health.
Target Products:
|
|
|
Outsourced Services |
|
|
Development/Manufacturing Services |
|
|
Contract Manufacturing Organizations (CMO) |
|
|
Pharmaceuticals |
|
|
Final Dosage Forms
Contract Manufacturing Organizations (CMO) that produce large quantities of drug products in final dosage forms ready to be sold to end users.
Target Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
Specialized Health Products Internat.
|
|
n/a | 20.976 | n/a | n/a | 3.00 | n/a | 40.42 | |
| Buyer | |||||||||
Johnson & Johnson
|
|
n/a | 173,713.146 | 16.88 | 15.82 | 3.44 | 3.27 | 6.76 | |
Abbott Laboratories
|
|
n/a | 64,622.293 | 19.32 | 16.50 | 2.89 | 2.94 | 14.51 | |
| Target | |||||||||
Wyeth
|
|
n/a | 63,950.250 | 17.43 | 15.44 | 3.41 | 3.13 | 8.12 | |
Bayer AG (ADR)
|
|
n/a | 31,455.824 | 16.33 | n/a | 0.95 | 0.99 | 7.68 | |
Cardinal Health, Inc.
|
|
n/a | 28,469.041 | 24.75 | 21.90 | 0.37 | 0.36 | 7.76 | |
Fresenius Medical Care AG & Co. (ADR)
|
|
n/a | 11,417.330 | 25.12 | 21.54 | 1.69 | 1.38 | -165.47 | |
Chiron Corporation
|
|
n/a | 9,459.472 | 51.16 | 27.90 | 4.93 | n/a | 5.84 | |
Hospira, Inc.
|
|
n/a | 6,289.492 | 26.17 | 20.26 | 2.39 | 2.32 | 5.14 | |
Rexam PLC (ADR)
|
|
n/a | 5,515.108 | 13.63 | 14.72 | 0.96 | 0.85 | -6.16 | |
Pall Corporation
|
|
n/a | 3,843.862 | 26.54 | 22.99 | 1.99 | 1.95 | 4.30 | |
Rhodia (ADR)
|
|
n/a | 3,294.808 | n/a | n/a | 0.48 | 0.47 | -2.46 | |
Abraxis BioScience, Inc.
|
|
n/a | 2,135.779 | 24.69 | 38.01 | 4.12 | 3.18 | 5.12 | |
Haemonetics Corporation
|
|
n/a | 1,460.343 | 23.38 | 27.39 | 3.57 | 3.37 | 3.86 | |
Crucell N.V. (ADR)
|
|
n/a | 1,121.797 | n/a | n/a | 24.31 | 22.10 | 6.77 | |
Alexion Pharmaceuticals, Inc.
|
|
n/a | 1,084.213 | n/a | -9.21 | 685.96 | 504.02 | 17.51 | |
The Medicines Company
|
|
n/a | 985.275 | n/a | 66.97 | 6.56 | 4.96 | 5.77 | |
Vital Signs, Inc.
|
|
n/a | 663.419 | 24.47 | 21.56 | 3.38 | 3.18 | 4.27 | |
ICU Medical, Incorporated
|
|
n/a | 565.879 | 27.71 | 24.90 | 3.59 | 2.94 | 3.20 | |
Panacos Pharmaceuticals, Inc.
|
|
n/a | 367.947 | n/a | -8.16 | 350.09 | 616.30 | 4.30 | |
Acambis plc (ADR)
|
|
n/a | 367.226 | n/a | -7.34 | 5.26 | 5.68 | 3.00 | |
Akorn, Inc.
|
|
n/a | 361.371 | n/a | 101.00 | 8.12 | 4.61 | 11.72 | |
Omnicell, Inc.
|
|
n/a | 338.604 | n/a | 30.53 | 2.79 | 2.17 | 6.83 | |
NxStage Medical, Inc.
|
|
n/a | 266.259 | n/a | -7.53 | 44.42 | 15.65 | 3.95 | |
ThermoGenesis Corp.
|
|
n/a | 213.658 | n/a | -39.50 | 21.21 | n/a | 19.10 | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
Phase Forward Incorporated
|
|
n/a | 403.666 | 115.32 | 39.07 | 4.64 | 3.79 | 10.58 | |
| Buyer | |||||||||
Cardica, Inc.
|
|
65.00% | 76.851 | n/a | -4.84 | 80.69 | 38.16 | -8.60 | |
California Micro Devices
|
|
13.00% | 174.515 | 43.00 | 26.83 | 2.59 | 2.55 | 3.09 | |
| Target | |||||||||
Cisco Systems, Inc.
|
|
n/a | 127,193.580 | 23.36 | 20.62 | 4.90 | 4.62 | 7.47 | |
Teva Pharmaceutical Industries Ltd (ADR)
|
|
n/a | 25,581.879 | 23.81 | 20.50 | 4.87 | 3.14 | 8.73 | |
Computer Sciences Corporation
|
|
n/a | 10,979.025 | 13.14 | 18.10 | 0.75 | 0.76 | 4.23 | |
Mettler-Toledo International Inc.
|
|
n/a | 2,561.407 | 23.88 | 19.83 | 1.73 | 1.69 | 19.58 | |
Angiotech Pharmaceuticals, Inc. (USA)
|
|
n/a | 1,239.085 | n/a | 18.64 | 6.21 | 3.91 | 3.34 | |
Ariba, Inc.
|
|
n/a | 681.235 | n/a | 23.72 | 2.18 | 2.22 | -22.30 | |
InterMune, Inc.
|
|
n/a | 598.137 | n/a | -12.88 | 5.41 | 6.10 | 19.87 | |
webMethods, Inc.
|
|
n/a | 498.812 | 139.82 | 38.00 | 2.47 | 2.42 | 3.55 | |
Hudson Highland Group, Inc.
|
|
n/a | 456.267 | 89.29 | 29.19 | 0.32 | 0.31 | 4.47 | |
SkyePharma PLC (ADR)
|
|
n/a | 421.950 | n/a | n/a | 3.48 | n/a | -3.81 | |
Phase Forward Incorporated
|
|
n/a | 403.666 | 115.32 | 39.07 | 4.64 | 3.79 | 10.58 | |
Capital Lease Funding, Inc.
|
|
n/a | 294.012 | 64.05 | 11.04 | 4.02 | 2.31 | 1.09 | |
Cerus Corporation
|
|
n/a | 198.956 | 16.23 | -7.63 | 8.16 | 7.33 | 5.64 | |
Dyax Corp.
|
|
n/a | 180.448 | n/a | -5.21 | 9.09 | 9.32 | 4.63 | |
ZEVEX International, Inc
|
|
n/a | 70.381 | 34.93 | n/a | 2.32 | n/a | 6.59 | |
CFC International, Inc.
|
|
n/a | 53.016 | 12.21 | 12.26 | 0.60 | n/a | 1.63 | |
Interlink Electronics
|
|
n/a | 39.791 | n/a | n/a | 1.03 | n/a | 1.21 | |
MTM Technologies, Inc.
|
|
n/a | 39.703 | n/a | n/a | 0.20 | n/a | 15.67 | |
XATA Corporation
|
|
n/a | 37.146 | n/a | n/a | 1.75 | 1.42 | 8.14 | |
Attunity Ltd.
|
|
n/a | 34.834 | n/a | n/a | 2.30 | n/a | -44.64 | |
HEI, Inc.
|
|
n/a | 24.931 | n/a | n/a | 0.46 | n/a | 2.04 | |
Cangene Corporation
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
Johnson & Johnson
|
|
n/a | 173,713.146 | 16.88 | 15.82 | 3.44 | 3.27 | 6.76 | |
Viacell, Inc.
|
|
n/a | 220.807 | n/a | -13.90 | 4.97 | 4.06 | 4.45 | |
Chindex International, Inc.
|
|
n/a | 70.307 | n/a | n/a | 0.69 | n/a | 3.11 | |
| Target | |||||||||
Premier, Inc.
|
|
7.70% | n/a | n/a | n/a | n/a | n/a | n/a | |
Cardinal Health, Inc.
|
|
n/a | 28,469.041 | 24.75 | 21.90 | 0.37 | 0.36 | 7.76 | |
Medco Health Solutions Inc.
|
|
n/a | 16,629.602 | 26.04 | 20.86 | 0.44 | 0.39 | -97.99 | |
Zimmer Holdings, Inc.
|
|
n/a | 16,489.028 | 22.51 | 19.46 | 5.02 | 4.64 | 11.01 | |
Chiron Corporation
|
|
n/a | 9,459.472 | 51.16 | 27.90 | 4.93 | n/a | 5.84 | |
MedImmune, Inc.
|
|
n/a | 7,816.641 | n/a | 82.03 | 6.28 | 5.67 | 6.27 | |
Amylin Pharmaceuticals
|
|
n/a | 5,865.863 | n/a | -28.19 | 41.76 | 14.15 | 89.45 | |
United Therapeutics Corporation
|
|
n/a | 1,419.782 | 21.54 | 29.64 | 12.25 | 9.54 | 5.42 | |
MGi Pharma, Inc.
|
|
n/a | 1,391.738 | n/a | 254.86 | 4.98 | 3.78 | -40.13 | |
Acambis plc (ADR)
|
|
n/a | 367.226 | n/a | -7.34 | 5.26 | 5.68 | 3.00 | |
Cerus Corporation
|
|
n/a | 198.956 | 16.23 | -7.63 | 8.16 | 7.33 | 5.64 | |
Allos Therapeutics, Inc.
|
|
n/a | 173.499 | n/a | -5.01 | n/a | 4.66 | 3.26 | |
Neurobiological Tech.
|
|
n/a | 103.723 | n/a | -6.27 | 19.57 | 18.15 | -29.32 | |
Praecis Pharmaceuticals
|
|
n/a | 48.465 | n/a | n/a | 6.37 | n/a | 0.95 | |
Curative Health Services, Inc.
|
|
n/a | 0.846 | n/a | n/a | 0.00 | 0.00 | -0.01 | |
National Health Service (United Kingdom)
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
Cyclacel Pharmaceuticals, Inc.
|
|
n/a | n/a | n/a | -4.62 | n/a | n/a | n/a | |
United States Government
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
General Electric Company
|
|
n/a | 361,460.204 | 22.27 | 17.15 | 2.41 | 2.24 | 13.08 | |
Johnson & Johnson
|
|
n/a | 173,713.146 | 16.88 | 15.82 | 3.44 | 3.27 | 6.76 | |
| Target | |||||||||
Cardinal Health, Inc.
|
|
n/a | 28,469.041 | 24.75 | 21.90 | 0.37 | 0.36 | 7.76 | |
Teva Pharmaceutical Industries Ltd (ADR)
|
|
n/a | 25,581.879 | 23.81 | 20.50 | 4.87 | 3.14 | 8.73 | |
Medco Health Solutions Inc.
|
|
n/a | 16,629.602 | 26.04 | 20.86 | 0.44 | 0.39 | -97.99 | |
Zimmer Holdings, Inc.
|
|
n/a | 16,489.028 | 22.51 | 19.46 | 5.02 | 4.64 | 11.01 | |
Chiron Corporation
|
|
n/a | 9,459.472 | 51.16 | 27.90 | 4.93 | n/a | 5.84 | |
MedImmune, Inc.
|
|
n/a | 7,816.641 | n/a | 82.03 | 6.28 | 5.67 | 6.27 | |
Amylin Pharmaceuticals
|
|
n/a | 5,865.863 | n/a | -28.19 | 41.76 | 14.15 | 89.45 | |
PDL BioPharma Inc.
|
|
n/a | 3,368.372 | n/a | 70.95 | 12.04 | 7.92 | 47.43 | |
Nektar Therapeutics
|
|
n/a | 1,889.833 | n/a | -16.72 | 14.97 | 11.21 | 8.08 | |
Haemonetics Corporation
|
|
n/a | 1,460.343 | 23.38 | 27.39 | 3.57 | 3.37 | 3.86 | |
United Therapeutics Corporation
|
|
n/a | 1,419.782 | 21.54 | 29.64 | 12.25 | 9.54 | 5.42 | |
MGi Pharma, Inc.
|
|
n/a | 1,391.738 | n/a | 254.86 | 4.98 | 3.78 | -40.13 | |
Angiotech Pharmaceuticals, Inc. (USA)
|
|
n/a | 1,239.085 | n/a | 18.64 | 6.21 | 3.91 | 3.34 | |
The Medicines Company
|
|
n/a | 985.275 | n/a | 66.97 | 6.56 | 4.96 | 5.77 | |
InterMune, Inc.
|
|
n/a | 598.137 | n/a | -12.88 | 5.41 | 6.10 | 19.87 | |
Threshold Pharmaceuticals, Inc.
|
|
n/a | 569.795 | n/a | -8.96 | 824.88 | 484.09 | 6.38 | |
SkyePharma PLC (ADR)
|
|
n/a | 421.950 | n/a | n/a | 3.48 | n/a | -3.81 | |
Acambis plc (ADR)
|
|
n/a | 367.226 | n/a | -7.34 | 5.26 | 5.68 | 3.00 | |
Cerus Corporation
|
|
n/a | 198.956 | 16.23 | -7.63 | 8.16 | 7.33 | 5.64 | |
Critical Therapeutics, Inc.
|
|
n/a | 185.794 | n/a | -3.54 | 29.85 | 8.86 | 2.57 | |
Halozyme Therapeutics, Inc.
|
|
n/a | 184.513 | n/a | -16.06 | 1,425.86 | n/a | 10.13 | |
Dyax Corp.
|
|
n/a | 180.448 | n/a | -5.21 | 9.09 | 9.32 | 4.63 | |
Allos Therapeutics, Inc.
|
|
n/a | 173.499 | n/a | -5.01 | n/a | 4.66 | 3.26 | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 3,550.6 | 9,875.0 | 13,425.6 |
Other Revenue
|
0.0 | 0.0 | 0.0 |
| Total Revenue | 3,550.6 | 9,875.0 | 13,425.6 |
Cost of Revenue
|
929.5 | 5,621.0 | 6,550.5 |
SG&A Expense
|
1,394.0 | 2,074.0 | 3,468.0 |
Depreciation & Amortization
|
22.2 | 0.0 | 22.2 |
Research & Development
|
598.0 | 538.0 | 1,136.0 |
Interest Expense
|
-57.4 | 0.0 | -57.4 |
Other Operating Expense
|
0.0 | 0.0 | 0.0 |
Unusual Expense (Income)
|
135.0 | -32.0 | 103.0 |
| Total Expenses | 3,021.3 | 8,201.0 | 11,222.3 |
Operating Income
|
529.3 | 1,674.0 | 2,203.3 |
| Non Operating Items | |||
Interest Expense (Inc.), Net Non-Oprtng
|
0.0 | -105.0 | -105.0 |
Other, Net
|
0.0 | -69.0 | -69.0 |
| Income Before Taxes | 529.3 | 1,500.0 | 2,029.3 |
| Income Taxes | 85.7 | 484.0 | 569.7 |
| Income After Taxes | 443.6 | 1,016.0 | 1,459.6 |
Net Income - Excl. Xord. Items
|
443.6 | 1,016.0 | 1,459.6 |
| Discontinued Operations | -29.7 | -4.0 | -33.7 |
Net Income - Incl. Xord. Items
|
413.9 | 1,012.0 | 1,425.9 |
Income Avail. to Common
|
413.9 | 1,012.0 | 1,425.9 |
| Share Items | |||
Basic Avg. Shares Outstanding
|
329.9 | 641.0 | 970.9 |
Basic EPS - Excl. Xord. Items
|
1.37 | 1.62 | 1.50 |
Basic EPS - Incl. Xord. Items
|
1.28 | 1.61 | 1.47 |
| Full Dilution Adjustment | 0.0 | 0.0 | 0.0 |
| Fully Diluted Shares Outstanding | 335.9 | 648.0 | 983.9 |
F.D. EPS - Excl. Xord. Items
|
1.34 | 1.60 | 1.48 |
F.D. EPS - Incl. Xord. Items
|
1.25 | 1.59 | 1.45 |
| Dividends Per Common Share | 0.40 | 0.58 | 0.98 |
| Balance Sheet | |||
| Assets | |||
Cash and Equivalents
|
2,383.7 | 881.0 | 3,264.7 |
ST Investments
|
450.9 | 0.0 | 450.9 |
Accounts Receivable
|
710.3 | 1,750.0 | 2,460.3 |
Inventory
|
397.2 | 2,006.0 | 2,403.2 |
Prepayments and Advances
|
89.1 | 0.0 | 89.1 |
Other Current Assets
|
465.7 | 594.0 | 1,059.7 |
Current Assets
|
4,496.9 | 5,231.0 | 9,727.9 |
PPE
|
1,828.8 | 0.0 | 1,828.8 |
Accum D&A
|
-867.2 | 0.0 | -867.2 |
PPE, Net
|
961.6 | 4,122.0 | 5,083.6 |
| Goodwill & Intangibles | 599.1 | 0.0 | 599.1 |
| Long Term Investments | 87.2 | 0.0 | 87.2 |
| Other Assets | 0.0 | 0.0 | 0.0 |
Other LT Assets
|
134.6 | 3,427.0 | 3,561.6 |
| Total Assets | 6,279.4 | 12,780.0 | 19,059.4 |
| Liabilities | |||
| Accounts Payable | 91.8 | 0.0 | 91.8 |
| Payable/Accrued | 0.0 | 0.0 | 0.0 |
ST Debt
|
349.8 | 129.0 | 478.8 |
| Other (Current) Liabilities | 876.0 | 2,796.0 | 3,672.0 |
Current Liab.
|
1,317.6 | 2,925.0 | 4,242.6 |
LT Debt
|
9.2 | 2,276.0 | 2,285.2 |
Total LT Debt
|
9.2 | 2,276.0 | 2,285.2 |
Other LT Liab.
|
241.6 | 1,832.0 | 2,073.6 |
Total Liabilities
|
1,568.4 | 7,033.0 | 8,601.4 |
| Shareholders Equity | |||
| Common Stock | 1,095.4 | 0.0 | 1,095.4 |
| Additional Paid in Capital | 602.1 | 0.0 | 602.1 |
| Retained Earnings | 2,940.9 | 0.0 | 2,940.9 |
| Other Equity | 81.1 | 5,747.0 | 5,828.1 |
| ESOP Debt Guarantee | -8.5 | 0.0 | -8.5 |
Total Equity
|
4,711.0 | 5,747.0 | 10,458.0 |
Total Liab. & Equity
|
6,279.4 | 12,780.0 | 19,059.4 |
Shares Outstanding
|
333.8 | 641.0 | 974.8 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | 413.9 | 1,014.0 | 1,427.9 |
| CF Depreciation | 144.2 | 572.0 | 716.2 |
| CF Amortization | 22.2 | 0.0 | 22.2 |
| CF Deferred Taxes | -317.0 | 180.0 | -137.0 |
| Other Non-Cash Items | 319.9 | 165.0 | 484.9 |
| Change in Working Capital | 412.6 | -348.0 | 64.6 |
| Total Cash From Operating Activities | 995.8 | 1,583.0 | 2,578.8 |
| Investing Cash Flow | |||
| Capital Expenditures | -310.1 | -455.0 | -765.1 |
| Other Investing Cash Flows | -218.3 | 28.0 | -190.3 |
| Total Cash From Investing Activities | -528.4 | -427.0 | -955.4 |
| Financing Cash Flow | |||
| Dividends Paid | -130.6 | -363.0 | -493.6 |
| Purchase Or Sale of Stock | 462.2 | 1,201.0 | 1,663.2 |
| Purchase and Retirement of Debt | -299.6 | -1,292.0 | -1,591.6 |
| Other Financing Cash Flow | 0.0 | -29.0 | -29.0 |
| Total Cash From Financing Activities | 32.0 | -483.0 | -451.0 |
| Exchange Rate Effects | -9.9 | -23.0 | -32.9 |
| Net Change in Cash | 489.5 | 650.0 | 1,139.5 |
| Cash Taxes Paid | 39.4 | 176.0 | 215.4 |
| Cash Interest Paid | 30.5 | 159.0 | 189.5 |
Specialized Health Products Internat.